



| ORLISTAT USP | | | | | | |
|---------------------|-----------|-----------------|---------------------|---------------------|--|--|
| PRODUCT CODE: 5 | | CAS Nº: 96829-5 | 8-2 AI | ANALYSIS Nº: 127/25 | | |
| MANUFACTURER BATCH: | 202504002 | | CERTIFICATE ID: | 46.504 | | |
| SUPPLIER BATCH: | | | MANUFACTURING DATE: | : 02/04/2025 | | |
| МЕТАРН ВАТСН: | 0140525 | | EXPIRY DATE: | 01/04/2028 | | |

| ATTRIBUTES | SHOULD BE | IS | |
|------------------------------|--|--------------------------|--|
| Description | White to off-white fine powder or fine powder with | White crystalline powder | |
| | lumps | | |
| Identification A | Complies | Complies | |
| Identification B | Complies | Complies | |
| Assay | 98.0 - 101.5 % | 99.9 % | |
| Residue on ignition | =< 0.1 % | 0.08 % | |
| Limit Related Compound A | =< 0.2 % | < 0.2 % | |
| Limit Related Compound B | =< 0.05 % | < 0.003 % | |
| Organic Impurities | | | |
| Formylleucine | =< 0.2 % | Not Detected | |
| Related compound C | =< 0.05 % | < 0.001 % | |
| Open ring epimer | =< 0.2 % | 0.08 % | |
| D-leucine | =< 0.2 % | Not Detected | |
| Any individual unspecified | =< 0.1 % | < 0.1 % (#) | |
| impurity | | | |
| Total impurities | =< 1.0 % | 0.1 % | |
| Limit Related Compound D and | | | |
| Open ring amide | | | |
| Related Compound D | =< 0.2 % | 0.03 % | |
| Open ring amide | =< 0.1 % | 0.02 % | |
| Limit Related Compound E | =< 0.2 % | < 0.2 % | |
| Water | =< 0.2 % | 0.03 % | |
| Specific optical rotation | -48º / -51º | -500 | |
| COMPLIES WITH | | | |

USP 2025

REMARKS

(#) Unspecified impurities detailed underneath:

RT 6.1 min) = 0.03 %

 $RT (6.7 \, min) = 0.02 \, \%$

Product fully analyzed within the EU, in compliance with the currents regulations "EudraLex - Volume 4 - Good Manufacturing Practice (GMP) guidelines" Part-II.

Orlistat is subjected to the requirements of the ICH Q3D "Elemental Impurities" guideline and the requirements of guides EMA/CHMP/ICH/82260/2006.

All data controlled by Metapharmaceutical Industrial SL.

Absence of N-nitrosamines impurities has been ensured after a risk evaluation according to ICH Q9, ICH M7 and in accordance with guidelines EMA/428592/2019 Rev 2 and EMA/189634/2019.

Certificates of residual solvents, allergens, non-GMO and BSE-TSE, among others, are available upon request.

All methods of analysis are validated by official pharmacopoeias or are validated by internal methods of the manufacturer, which can be obtained at specific request. The above information does not exempt from the obligation to identify the product before use.

Analysis date: 10/09/2025

Signature: Albert Sánchez López (QP)

Conclusion: Complies

Original certificate available upon request

Manufacturer: 40001546

ARGUS PHARMACEUTICALS LTD.

Linyu Road, 178

Changsha National High-Tech Industrial

Development Zone

Page 1 of 2 A073.03.ENG





| ORLISTAT USP | | | | | | |
|---------------------|-----------|----------------|--------------------------|--|--|--|
| PRODUCT CODE: 5 | CAS | Nº: 96829-58-2 | ANALYSIS Nº: 127/25 | | | |
| MANUFACTURER BATCH: | 202504002 | CERTIFI | CATE ID: 46.504 | | | |
| SUPPLIER BATCH: | | MANUFA | CTURING DATE: 02/04/2025 | | | |
| МЕТАРН ВАТСН: | 0140525 | EXPIRY | DATE: 01/04/2028 | | | |

STORAGE

Protect from light and heat. Transport temperature 2 - 8 °C

Analysis date: 10/09/2025

Signature: Albert Sánchez López (QP)

Conclusion: Complies

Original certificate available upon request

Manufacturer: 40001546

ARGUS PHARMACEUTICALS LTD.

Linyu Road, 178

Changsha National High-Tech Industrial

Development Zone

A073.03.ENG